Abstract
Background: Several previous researchers have investigated the prognostic value of serum tumor markers, especially carcinoembryonic antigen (CEA). Only a limited number of studies reported the usefulness of serum tumor markers for lung squamous cell carcinoma (SQ). We aimed to examine the significance of serum tumor markers for lung SQ. Methods: Eighty-five lung SQ patients who underwent surgery and followed more than 5-year were included. The ratios of 5-year survivors to all patients in groups with several clinicopathologic factors, including tumor markers, were compared. We also compared the clinicopathologic factors between central type and peripheral type SQ. Results: The majority of patients were male gender and current/ former smokers. Age, pN status, cytokeratin-19 fragment (CYFRA 21-1), squamous cell carcinoma antigen (SCC), and comorbid interstitial pneumonia (IP) were associated with the ratio of 5-year survivors significantly. When patients were compared based on tumor location, high p-stage and CYFRA 21-1 were related to central type SQ. Conclusion: Both SCC and CYFRA 21-1 appeared to be useful prognostic markers for patients with lung SQ. Furthermore, CYFRA 21-1 was related to central type SQ.
Highlights
Serum tumor markers have been investigated as prognostic factors for non-small cell lung cancer (NSCLC)
CYFRA 21-1 was related to central type squamous cell carcinoma (SQ)
Prognostic role of carcinoembryonic antigen (CEA) [1] [2] [3], only a limited number of recent previous studies reported the prognostic role of squamous cell carcinoma antigen (SCC) in NSCLC [2] [4] [5] [6]
Summary
Serum tumor markers have been investigated as prognostic factors for non-small cell lung cancer (NSCLC). Emerging evidence suggests that preoperative cytokeratin-19 fragment (CYFRA 21-1) is known as a useful tumor marker for NSCLC [2] [3] [7] [8] Both SCC and CYFRA 21-1 are generally known to be sensitive to squamous cell carcinoma (SQ) as compared to AD [2] [4] [5] [7] [8]. CYFRA 21-1 was related to central type SQ
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
